comparemela.com

Latest Breaking News On - டாகேடா மருந்துகள் - Page 19 : comparemela.com

HIV patients are more likely to die from COVID-19 infection

HIV patients are more likely to die from COVID-19 infection Over the past year, studies have revealed that certain pre-existing conditions, such as cancer, diabetes and high blood pressure, can increase a person s risk of dying from COVID-19. New research shows that individuals living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) -; an estimated 38 million worldwide, according to the World Health Organization -; have an increased risk of SARS-CoV-2 infection and fatal outcomes from COVID-19. In a new study, Penn State College of Medicine researchers found that people living with HIV had a 24% higher risk of SARS-CoV-2 infection and a 78% higher risk of death from COVID-19 than people without HIV. They assessed data from 22 previous studies that included nearly 21 million participants in North America, Africa, Europe and Asia to determine to what extent people living with HIV/AIDS are susceptible to SARS-CoV-2 infection and death from COVID-1

Xenetic Biosciences, Inc Reports First Quarter 2021 Financial Results

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement FRAMINGHAM, MA / ACCESSWIRE / May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ( Xenetic or the Company ), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the first quarter of 2021 and provided a corporate update. During the first quarter our focus remained on advancing the development of our XCART platform, which we believe has the potential to provide a personalized CAR T therapy targeting cancers with a patient-and tumor-specific approach. The commencement of our exploratory patient biopsy trial is a key component of our preclinical development strategy and an important step forward toward advancing into a Phase 1 study, com

InveniAI Appoints Industry Leader Dr Salvatore Alesci as

InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis May 11, 2021 08:10 ET | Source: InveniAI LLC InveniAI LLC Guilford, Connecticut, UNITED STATES Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseases Dr. Alesci’s proven track record in optimizing early-stage drug development of multiple programs in various therapeutic areas will be key as the company leverages its AI-platform to advance and diversify its portfolio GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) InveniAI ® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the appointment of Sa

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.